{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:49:45Z","timestamp":1793227785451,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bbalip.2019.07.006","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T12:02:30Z","timestamp":1563364950000},"page":"1422-1437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Ursodeoxycholic acid is a GPBAR1 agonist and resets liver\/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH"],"prefix":"10.1016","volume":"1864","author":[{"given":"Adriana","family":"Carino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marchian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Fiorucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zampella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Scarpelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fiorucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbalip.2019.07.006_bb0005","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s10620-016-4143-0","article-title":"Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations","volume":"6","author":"Sherif","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0020","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. (64) 2016 1388\u20131402. doi: https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.phrs.2018.07.014","article-title":"Future trends in the treatment of non-alcoholic steatohepatitis","volume":"134","author":"Fiorucci","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.molmed.2015.09.001","article-title":"Bile acid-activated receptors, intestinal microbiota and the treatment of metabolic disorders","volume":"21","author":"Fiorucci","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0035","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile acids activated receptors regulate innate immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0040","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0050","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0055","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tips.2009.08.001","article-title":"Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders","volume":"30","author":"Fiorucci","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.21458","article-title":"The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells","volume":"45","author":"Keitel","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0065","doi-asserted-by":"crossref","unstructured":"B. Goodwin, S.A. Jones, R.R Price, M.A. Watson, D.D. McKee, L.B. Moore, C. Galardi, J.G. Wilson, M.C Lewis, M.E. Roth, P.R. Maloney, T.M. Willson, S.A. Kliewer, A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell. 6 (2000) 517\u2013526.","DOI":"10.1016\/S1097-2765(00)00051-4"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","article-title":"FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats","volume":"51","author":"Cipriani","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0075","doi-asserted-by":"crossref","unstructured":"B.A. Neuschwander-Tetri, R. Loomba, A.J. Sanyal, J.E Lavine, M.L. Van Natta, M.F. Abdelmalek, N. Chalasani, S. Dasarathy, A.M. Diehl, B. Hameed, K.V. Kowdley, A. McCullough, N. Terrault, J.M. Clark, J. Tonascia, E.M. Brunt, D.E. Kleiner, E. Doo, NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015) 956\u2013965.","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0085","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"12","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0095","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0100","doi-asserted-by":"crossref","first-page":"13689","DOI":"10.1038\/s41598-017-13102-y","article-title":"Gpbar1 agonism promotes a Pgc-1\u03b1-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0105","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The bile acid receptor GPBAR1 regulates the M1\/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0110","doi-asserted-by":"crossref","unstructured":"A. Carino, S. Marchian\u00f2, M. Biagioli, M. Bucci, V. Vellecco, V. Brancaleone, C. Fiorucci, A. Zampella, M.C. Monti, E. Distrutti, S. Fiorucci, Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. FASEB J. (2018) fj201801373RR. doi: https:\/\/doi.org\/10.1096\/fj.201801373RR.","DOI":"10.1096\/fj.201801373RR"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0115","doi-asserted-by":"crossref","unstructured":"R. Pellicciari, S. Fiorucci, E. Camaioni, C. Clerici, G. Costantino, P.R. Maloney, A. Morelli, D.J Parks, T.M. Willson, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45 (2002) 3569\u20133572.","DOI":"10.1021\/jm025529g"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0120","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0168-8278(16)00372-X","article-title":"Regenerate: a phase 3, double blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis","volume":"64","author":"Ratziu","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0125","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"POISE study group. a placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0130","unstructured":"FDA adds boxed warning to highlight correct dosing of Ocaliva (Obeticholic Acid) for patients with a rare chronic liver disease. (2018) https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm594941.htm"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0135","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/bbrc.1999.1403","article-title":"Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants","volume":"263","author":"Mitsuyoshi","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11745-017-4242-5","article-title":"Ursodeoxycholic acid suppresses lipogenesis in mouse liver: possible role of the decrease in \u03b2-muricholic acid, a farnesoid X receptor antagonist","volume":"52","author":"Fujita","year":"2017","journal-title":"Lipids."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0145","doi-asserted-by":"crossref","unstructured":"V. Ratziu, Treatment of NASH with ursodeoxycholic acid: pro. Clin. Res. Hepatol. Gastroenterol. 36 (2012) Suppl 1:S41-S45. doi: https:\/\/doi.org\/10.1016\/S2210-7401(12)70020-7.","DOI":"10.1016\/S2210-7401(12)70020-7"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0150","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0155","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0160","doi-asserted-by":"crossref","unstructured":"V. Ratziu, V. de Ledinghen, F. Oberti, P. Mathurin, C. Wartelle-Bladou, C. Renou, P. Sogni, M. Maynard, D. Larrey, L. Serfaty, D. Bonnefont-Rousselot, J.P. Bastard, M. Rivi\u00e8re, J. Sp\u00e9nard ; FRESGUN, A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J. Hepatol. 54 (2011) 1011\u20131019. doi: https:\/\/doi.org\/10.1016\/j.jhep.2010.08.030.","DOI":"10.1016\/j.jhep.2010.08.030"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.90","article-title":"Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice","volume":"46","author":"Kim","year":"2014","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0170","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0175","doi-asserted-by":"crossref","first-page":"26913","DOI":"10.1074\/jbc.M111.248203","article-title":"Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure","volume":"286","author":"Watanabe","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0180","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0185","doi-asserted-by":"crossref","first-page":"43782","DOI":"10.1038\/srep43782","article-title":"Elevated fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice","volume":"7","author":"Morrice","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0190","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0200","doi-asserted-by":"crossref","first-page":"8988","DOI":"10.1074\/jbc.M212633200","article-title":"Repression of farnesoid X receptor during the acute phase response","volume":"278","author":"Kim","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nutres.2017.07.006","article-title":"Diet-induced obesity and weight loss alter bile acid concentrations and bile acid-sensitive gene expression in insulin target tissues of C57BL\/6J mice","volume":"46","author":"La Frano","year":"2017","journal-title":"Nutr. Res."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0210","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0215","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0220","doi-asserted-by":"crossref","unstructured":"V. Sepe, B. Renga, C. Festa, C. D'Amore, D. Masullo, S. Cipriani, F.S. Di Leva, M.C. Monti, E. Novellino, V. Limongelli, A. Zampella, S. Fiorucci, Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). J. Med. Chem. 57 (2014) 7687\u20137701. doi: https:\/\/doi.org\/10.1021\/jm500889f.","DOI":"10.1021\/jm500889f"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0225","doi-asserted-by":"crossref","unstructured":"K.R. Shima, T. Ota, K.I. Kato, Y. Takeshita, H. Misu, S. Kaneko, T. Takamura, Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study. B.M.J. Open Diabetes Res. Care. 6 (2018) e000469. doi: https:\/\/doi.org\/10.1136\/bmjdrc-2017-000469.","DOI":"10.1136\/bmjdrc-2017-000469"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0230","doi-asserted-by":"crossref","unstructured":"H. Schrem, J. Klempnauer, J. Borlak, Liver-enriched transcription factors in liver function and development. Part II: the C\/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol. Rev. 56 (2004) 291\u2013330.","DOI":"10.1124\/pr.56.2.5"},{"key":"10.1016\/j.bbalip.2019.07.006_bb0235","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.canep.2013.03.010","article-title":"Effects of polymorphisms in alcohol metabolism and oxidative stress genes on survival from head and neck cancer","volume":"37","author":"Hakenewerth","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0240","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.fct.2017.08.010","article-title":"Docosahexaenoic acid increases the expression of oxidative stress-induced growth inhibitor 1 through the PI3K\/Akt\/Nrf2 signaling pathway in breast cancer cells","volume":"108","author":"Tsai","year":"2017","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0245","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An obesity-associated gut microbiome with increased capacity for energy harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0250","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1053\/j.gastro.2018.08.022","article-title":"FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid","volume":"155","author":"Friedman","year":"2018","journal-title":"Gastroenterology."},{"key":"10.1016\/j.bbalip.2019.07.006_bb0255","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology."}],"updated-by":[{"DOI":"10.1016\/j.bbalip.2026.159776","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:00:00Z","timestamp":1792972800000}}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138819811930126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138819811930126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:05:27Z","timestamp":1761386727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138819811930126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S138819811930126X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbalip.2019.07.006","relation":{},"ISSN":["1388-1981"],"issn-type":[{"value":"1388-1981","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ursodeoxycholic acid is a GPBAR1 agonist and resets liver\/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbalip.2019.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}